ADCETRIS

Indicaton

SeaGen's lead product ADCETRIS® (brentuximab vedotin) is marketed in over 70 countries worldwide for the treatment of CD30-expressing lymphomas, in collaboration with Takeda Pharmaceutical Company Limited.

Therapeutic indications

Oncology

Type of product

Antibody

Table

Phase

Marketed
Partnering status

Partnered
Partner

Takeda Pharmaceutical Company Limited.
Available in

EU, US, LATAM, JAPAC, Switzerland

You may also be interested in

Proclarix

Proclarix® is CE marked, intended for in vitro diagnostic use and indicated for prostate cancer diagnosis in patients with normal digital rectal exam (DRE), enlarged prostate volume and elevated levels of PSA at 2-10 ng/ml.

Marketed

C-PTBE-01

C-PTBE-01 has shown a strong steroid-sparing effect in two clinical safety and efficacy studies in patients with brain tumors and peritumoral brain edema (PTBE). C-PTBE-01 can lead to a market reduction or complete replacement of steroid use. This can alleviate the severe steroid-induced side effects and thus improve the quality of life of those affected.

Phase II completed

Breast cancer screening test

Xemperia flag-ship project is a PCR-based blood test for breast cancer screening. The technology can be adapted to other cancers, immune, inflammatory and cardiovascular diseases. Xemperia's pipeline also includes DNA based nansensors for the ultrasensitive detection of nucleic acids.

Phase II completed